- Home
- DCGO vs THRD Comparison
DCGO vs THRD Comparison
Compare DCGO & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCGO
- THRD
- Stock Information
- Founded
- DCGO 2015
- THRD 2019
- Country
- DCGO United States
- THRD United States
- Employees
- DCGO N/A
- THRD N/A
- Industry
- DCGO Managed Health Care
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- DCGO Health Care
- THRD Health Care
- Exchange
- DCGO Nasdaq
- THRD Nasdaq
- Market Cap
- DCGO 415.2M
- THRD 335.2M
- IPO Year
- DCGO N/A
- THRD 2022
- Fundamental
- Price
- DCGO $4.31
- THRD $6.00
- Analyst Decision
- DCGO Strong Buy
- THRD Strong Buy
- Analyst Count
- DCGO 5
- THRD 3
- Target Price
- DCGO $6.10
- THRD $20.33
- AVG Volume (30 Days)
- DCGO 465.2K
- THRD 248.2K
- Earning Date
- DCGO 02-26-2025
- THRD 11-07-2024
- Dividend Yield
- DCGO N/A
- THRD N/A
- EPS Growth
- DCGO 300.38
- THRD N/A
- EPS
- DCGO 0.29
- THRD N/A
- Revenue
- DCGO $694,968,328.00
- THRD N/A
- Revenue This Year
- DCGO $2.14
- THRD N/A
- Revenue Next Year
- DCGO N/A
- THRD N/A
- P/E Ratio
- DCGO $15.02
- THRD N/A
- Revenue Growth
- DCGO 30.19
- THRD N/A
- 52 Week Low
- DCGO $2.75
- THRD $5.60
- 52 Week High
- DCGO $4.86
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- DCGO 54.31
- THRD 23.75
- Support Level
- DCGO $3.95
- THRD $5.60
- Resistance Level
- DCGO $4.34
- THRD $11.78
- Average True Range (ATR)
- DCGO 0.19
- THRD 0.89
- MACD
- DCGO -0.01
- THRD -0.43
- Stochastic Oscillator
- DCGO 76.84
- THRD 6.50
About DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company has three reportable segments: Mobile Health Services, Transportation Services, and Corporate. Mobile Health Services is the key revenue-generating segment for the company.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.